Prelude Capital Management, LLC Akero Therapeutics, Inc. Transaction History
Prelude Capital Management, LLC
- $1.5 Billion
- Q4 2024
A detailed history of Prelude Capital Management, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 17,872 shares of AKRO stock, worth $752,768. This represents 0.03% of its overall portfolio holdings.
Number of Shares
17,872
Previous 16,300
9.64%
Holding current value
$752,768
Previous $467,000
6.42%
% of portfolio
0.03%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding AKRO
# of Institutions
210Shares Held
74.3MCall Options Held
321KPut Options Held
558K-
Wellington Management Group LLP Boston, MA7.38MShares$311 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY6.86MShares$289 Million3.11% of portfolio
-
Janus Henderson Group PLC London, X06.03MShares$254 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$235 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$220 Million5.21% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.96B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...